/
Pharmaceutical preparations company · MA · FY ends Dec · Revenue $12.22B · 38.31% margin · $3.71B FCF
Margins and capital returns are both well above average: 34.77% operating margin, ROIC at 17.93%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 8.9%, steady but not accelerating.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$12.22B
▲ +8.9% YoY
Net Income (TTM)
$4.34B
▲ +838.1% YoY
Op. Margin
38.31%
▲ +36.9pp YoY
ROIC
19.29%
▲ +18.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$3.71B
▲ +504.1% YoY
Op. Cash Flow (TTM)
$4.24B
▲ +837.2% YoY
Net Debt
-$5.26B
Net Cash Position
Cash & Equiv.
$7.25B
5Y CAGR: +14.1%
5Y CAGR: +1.3%
Continue Research